Resolute Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Resolute Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,600	Closed	-$77K	–	84
2022 Q3	$77K	Hold	9,600	–	–	0.01%	70
2022 Q2	$67K	Hold	9,600	–	–	0.01%	68
2022 Q1	$145K	Sell	9,600 -21	-0.2%	-$330	0.01%	61
2021 Q4	$211K	Hold	9,621	–	–	0.01%	59
2021 Q3	$259K	Hold	9,621	–	–	0.04%	58
2021 Q2	$232K	Buy	9,621 +21	+0.2%	+$643	0.04%	44
2021 Q1	$416K	Buy	+9,600	New	+$425K	0.06%	36

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Resolute Advisors's FDMT Position: Q4 2022 in Review

Resolute Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 9,600 shares — an estimated $77K sold.

Resolute Advisors first reported a position in FDMT in Q1 2021 and held it in 7 quarters. The position peaked at $416K in Q1 2021. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

Resolute Advisors reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
Resolute Advisors sold 9,600 4D Molecular Therapeutics shares in Q4 2022, an estimated $77K.
Resolute Advisors first reported a position in 4D Molecular Therapeutics in Q1 2021 and held it in 7 quarters.
Resolute Advisors's 4D Molecular Therapeutics position peaked at $416K in Q1 2021.
96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Resolute Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.